Next Article in Journal
Colonized Sabethes cyaneus, a Sylvatic New World Mosquito Species, Shows a Low Vector Competence for Zika Virus Relative to Aedes aegypti
Previous Article in Journal
Molecular Characterization and Geographic Distribution of a Mymonavirus in the Population of Botrytis cinerea
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessArticle
Viruses 2018, 10(8), 433;

Potential Therapeutic Agents for Feline Calicivirus Infection

School of Biotechnology and Biomolecular Sciences, Faculty of Science, University of New South Wales, Sydney, NSW 2052, Australia
Laboratório de Virologia Comparada e Ambiental, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro 21040-900, Brazil
Author to whom correspondence should be addressed.
Received: 1 August 2018 / Revised: 14 August 2018 / Accepted: 15 August 2018 / Published: 16 August 2018
(This article belongs to the Section Antivirals & Vaccines)
Full-Text   |   PDF [8341 KB, uploaded 18 August 2018]   |  


Feline calicivirus (FCV) is a major cause of upper respiratory tract disease in cats, with widespread distribution in the feline population. Recently, virulent systemic diseases caused by FCV infection has been associated with mortality rates up to 50%. Currently, there are no direct-acting antivirals approved for the treatment of FCV infection. Here, we tested 15 compounds from different antiviral classes against FCV using in vitro protein and cell culture assays. After the expression of FCV protease-polymerase protein, we established two in vitro assays to assess the inhibitory activity of compounds directly against the FCV protease or polymerase. Using this recombinant enzyme, we identified quercetagetin and PPNDS as inhibitors of FCV polymerase activity (IC50 values of 2.8 μM and 2.7 μM, respectively). We also demonstrate the inhibition of FCV protease activity by GC376 (IC50 of 18 µM). Using cell culture assays, PPNDS, quercetagetin and GC376 did not display antivirals effects, however, we identified nitazoxanide and 2′-C-methylcytidine (2CMC) as potent inhibitors of FCV replication, with EC50 values in the low micromolar range (0.6 μM and 2.5 μM, respectively). In conclusion, we established two in vitro assays that will accelerate the research for FCV antivirals and can be used for the high-throughput screening of direct-acting antivirals. View Full-Text
Keywords: feline calicivirus; antivirals; nucleoside analogues; non-nucleoside inhibitors; protease inhibitors feline calicivirus; antivirals; nucleoside analogues; non-nucleoside inhibitors; protease inhibitors

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Fumian, T.M.; Tuipulotu, D.E.; Netzler, N.E.; Lun, J.H.; Russo, A.G.; Yan, G.J.H.; White, P.A. Potential Therapeutic Agents for Feline Calicivirus Infection. Viruses 2018, 10, 433.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top